| Kristen Lebleu Losavio, MD | |
|
5326 Odonovan Dr, Baton Rouge, LA 70808-4691 | |
| (225) 769-7546 | |
| (225) 769-0471 |
| Full Name | Kristen Lebleu Losavio |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 16 Years |
| Location | 5326 Odonovan Dr, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225203904 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | MD.205348 (Louisiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dermatology Clinic A Professional Medical Corporation | 6103856661 | 10 |
News Archive
In the quest to arrest the growth and spread of tumors, there have been many attempts to get cancer genes to ignore their internal instruction manual. In a new study, a team led by Dana-Farber Cancer Institute scientists has created the first molecule able to prevent cancer genes from "hearing" those instructions, stifling the cancer process at its root.
Wearables have proliferated in the marketplace, but there's still a lot of opportunity for growth. One of the ways in which wearables are limited is that people expect their wearables to really measure what they feel is important to be measured
Since the first television screens lit up our living rooms scientists have been studying its affect on young children. Now scientists in Ohio have compared mother-child communication while watching TV to reading books or playing with Toys to reveal the impact on children's development. The results, published in Human Communication Research, show that watching TV can lead to less interaction between parents and children, with a detrimental impact on literacy and language skills.
Nabi Biopharmaceuticals announced that it has initiated the second of two pivotal Phase III clinical trials for NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary vaccine to treat nicotine addiction and prevent smoking relapse. The FDA has agreed with Nabi on the study design, protocol and end points through a Special Protocol Assessment (SPA). The SPA forms a basic foundation to support approval of a New Drug Application. The Company also received scientific advice from the European Medicines Agency (EMEA) that confirms and supports the trial protocol.
› Verified 6 days ago
| Entity Name | Dermatology Clinic A Professional Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972591170 PECOS PAC ID: 6103856661 Enrollment ID: O20050816000153 |
News Archive
In the quest to arrest the growth and spread of tumors, there have been many attempts to get cancer genes to ignore their internal instruction manual. In a new study, a team led by Dana-Farber Cancer Institute scientists has created the first molecule able to prevent cancer genes from "hearing" those instructions, stifling the cancer process at its root.
Wearables have proliferated in the marketplace, but there's still a lot of opportunity for growth. One of the ways in which wearables are limited is that people expect their wearables to really measure what they feel is important to be measured
Since the first television screens lit up our living rooms scientists have been studying its affect on young children. Now scientists in Ohio have compared mother-child communication while watching TV to reading books or playing with Toys to reveal the impact on children's development. The results, published in Human Communication Research, show that watching TV can lead to less interaction between parents and children, with a detrimental impact on literacy and language skills.
Nabi Biopharmaceuticals announced that it has initiated the second of two pivotal Phase III clinical trials for NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary vaccine to treat nicotine addiction and prevent smoking relapse. The FDA has agreed with Nabi on the study design, protocol and end points through a Special Protocol Assessment (SPA). The SPA forms a basic foundation to support approval of a New Drug Application. The Company also received scientific advice from the European Medicines Agency (EMEA) that confirms and supports the trial protocol.
› Verified 6 days ago
| Entity Name | Dermatology And Aesthetic Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437371820 PECOS PAC ID: 5092806570 Enrollment ID: O20070813000650 |
News Archive
In the quest to arrest the growth and spread of tumors, there have been many attempts to get cancer genes to ignore their internal instruction manual. In a new study, a team led by Dana-Farber Cancer Institute scientists has created the first molecule able to prevent cancer genes from "hearing" those instructions, stifling the cancer process at its root.
Wearables have proliferated in the marketplace, but there's still a lot of opportunity for growth. One of the ways in which wearables are limited is that people expect their wearables to really measure what they feel is important to be measured
Since the first television screens lit up our living rooms scientists have been studying its affect on young children. Now scientists in Ohio have compared mother-child communication while watching TV to reading books or playing with Toys to reveal the impact on children's development. The results, published in Human Communication Research, show that watching TV can lead to less interaction between parents and children, with a detrimental impact on literacy and language skills.
Nabi Biopharmaceuticals announced that it has initiated the second of two pivotal Phase III clinical trials for NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary vaccine to treat nicotine addiction and prevent smoking relapse. The FDA has agreed with Nabi on the study design, protocol and end points through a Special Protocol Assessment (SPA). The SPA forms a basic foundation to support approval of a New Drug Application. The Company also received scientific advice from the European Medicines Agency (EMEA) that confirms and supports the trial protocol.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristen Lebleu Losavio, MD 5326 Odonovan Dr, Baton Rouge, LA 70808-4691 Ph: (225) 769-7546 | Kristen Lebleu Losavio, MD 5326 Odonovan Dr, Baton Rouge, LA 70808-4691 Ph: (225) 769-7546 |
News Archive
In the quest to arrest the growth and spread of tumors, there have been many attempts to get cancer genes to ignore their internal instruction manual. In a new study, a team led by Dana-Farber Cancer Institute scientists has created the first molecule able to prevent cancer genes from "hearing" those instructions, stifling the cancer process at its root.
Wearables have proliferated in the marketplace, but there's still a lot of opportunity for growth. One of the ways in which wearables are limited is that people expect their wearables to really measure what they feel is important to be measured
Since the first television screens lit up our living rooms scientists have been studying its affect on young children. Now scientists in Ohio have compared mother-child communication while watching TV to reading books or playing with Toys to reveal the impact on children's development. The results, published in Human Communication Research, show that watching TV can lead to less interaction between parents and children, with a detrimental impact on literacy and language skills.
Nabi Biopharmaceuticals announced that it has initiated the second of two pivotal Phase III clinical trials for NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary vaccine to treat nicotine addiction and prevent smoking relapse. The FDA has agreed with Nabi on the study design, protocol and end points through a Special Protocol Assessment (SPA). The SPA forms a basic foundation to support approval of a New Drug Application. The Company also received scientific advice from the European Medicines Agency (EMEA) that confirms and supports the trial protocol.
› Verified 6 days ago
Lauren Kathryn Petit, MD Dermatology Medicare: Medicare Enrolled Practice Location: 7373 Perkins Rd, Baton Rouge, LA 70808 Phone: 225-246-9790 Fax: 225-246-9160 | |
Tom J Meek Jr., MD Dermatology Medicare: Medicare Enrolled Practice Location: 5326 O'donovan Drive, Baton Rouge, LA 70808 Phone: 225-769-7546 Fax: 225-769-0471 | |
Jordan Lynn Whatley, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5326 Odonovan Dr, Baton Rouge, LA 70808 Phone: 225-769-7546 Fax: 225-769-0471 | |
Dr. Azeen Sadeghian, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 8585 Picardy Ave Ste 512, Baton Rouge, LA 70809 Phone: 253-333-6142 | |
Dr. Harry A Burglass Jr., MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5326 O'donovan Drive, Baton Rouge, LA 70808 Phone: 225-769-7546 Fax: 225-769-0471 | |
Sarah Mcginty, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 10154 Jefferson Hwy, Baton Rouge, LA 70809 Phone: 225-927-5663 Fax: 225-928-7341 | |
Courtney Murphy, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 7373 Perkins Rd, Baton Rouge, LA 70808 Phone: 225-769-4044 |